For Your Information
FTC Approves Final Order Preserving Competition in Market for Treating Heartworm Disease in Dogs
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Eli Lilly and Company’s acquisition of Novartis Animal Health would likely be anticompetitive.
Under the order, first announced in December 2014, Eli Lilly and Company has agreed to divest its Sentinel product line of medications for treating heartworm disease in dogs, and associated assets, to the French pharmaceutical company, Virbac S.A.
The Commission vote approving the final order was 5-0. (FTC File No. 141 0142; the staff contact is Michael Barnett, Bureau of Competition, 202-326-2362)
The Federal Trade Commission works to promote competition, and to protect and educate consumers. The FTC will never demand money, make threats, tell you to transfer money, or promise you a prize. You can learn more about how competition benefits consumers, file an antitrust complaint, or comment on a proposed merger. For the latest news and resources, follow the FTC on social media, subscribe to press releases, and read our blog.
Press Release Reference
Contact Information
MEDIA CONTACT:
Betsy Lordan
Office of Public Affairs
202-326-3707